The Japan arm of Ferring Pharmaceuticals said on June 26 that Jugo Tsumura will step down as its president and chief executive officer, effective June 30, for personal reasons. Minoru Inabayashi, head of business development and corporate planning, will become…
To read the full story
Related Article
- Ex-Sanofi Exec John Pulvar Tapped as New CEO of Ferring Japan
September 3, 2024
- Ex-Novartis Exec Jugo Tsumura Takes Reins at Ferring Japan
July 12, 2022
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





